Xing Liu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5165370/publications.pdf

Version: 2024-02-01

201674 161849 3,315 72 27 54 citations h-index g-index papers 74 74 74 3613 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Molecular subtyping of diffuse gliomas using magnetic resonance imaging: comparison and correlation between radiomics and deep learning. European Radiology, 2022, 32, 747-758.	4.5	31
2	Extended En Bloc Reoperation for Recurrent or Persistent Parathyroid Carcinoma: Analysis of 31 Cases in a Single Institute Experience. Annals of Surgical Oncology, 2022, 29, 1208-1215.	1.5	12
3	ASO Author Reflections: Extended En Bloc Reoperation: A Potential Curative Operation for Recurrent or Persistent Parathyroid Carcinoma. Annals of Surgical Oncology, 2022, 29, 1216-1217.	1.5	O
4	Recurrent PTPRZ1â€MET fusion and a high occurrence rate of MET exon 14 skipping in brain metastases. Cancer Science, 2022, 113, 796-801.	3.9	7
5	Prediction of H3 K27M-mutant in midline gliomas by magnetic resonance imaging: a systematic review and meta-analysis. Neuroradiology, 2022, 64, 1311-1319.	2.2	3
6	Hypoxia-induced acetylation of PAK1 enhances autophagy and promotes brain tumorigenesis via phosphorylating ATG5. Autophagy, 2021, 17, 723-742.	9.1	95
7	Expression profile of serum-related exosomal miRNAs from parathyroid tumor. Endocrine, 2021, 72, 239-248.	2.3	6
8	Clinical practice guidelines for the management of adult diffuse gliomas. Cancer Letters, 2021, 499, 60-72.	7.2	194
9	Prediction of H3K27M-mutant brainstem glioma by amide proton transfer–weighted imaging and its derived radiomics. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 4426-4436.	6.4	25
10	T-Cell Exhaustion Status Under High and Low Levels of Hypoxia-Inducible Factor $1\hat{l}\pm$ Expression in Glioma. Frontiers in Pharmacology, 2021, 12, 711772.	3.5	13
11	Preoperative Radiomics Analysis of 1p/19q Status in WHO Grade II Gliomas. Frontiers in Oncology, 2021, 11, 616740.	2.8	8
12	Molecular subtype impacts surgical resection in low-grade gliomas: A Chinese Glioma Genome Atlas database analysis. Cancer Letters, 2021, 522, 14-21.	7.2	10
13	LncRNA PRADX-mediated recruitment of PRC2/DDX5 complex suppresses UBXN1 expression and activates NF- \hat{I}^0 B activity, promoting tumorigenesis. Theranostics, 2021, 11, 4516-4530.	10.0	37
14	HOTAIR Up-Regulation Activates NF-κB to Induce Immunoescape in Gliomas. Frontiers in Immunology, 2021, 12, 785463.	4.8	14
15	ASO Visual Abstract: Extended En Bloc Reoperation for Recurrent or Persistent Parathyroid Carcinomaâ€"Analysis of 31 Cases in a Single-Institution Experience. Annals of Surgical Oncology, 2021, 29, 1218.	1.5	4
16	PTRF/Cavin-1 as a Novel RNA-Binding Protein Expedites the NF-κB/PD-L1 Axis by Stabilizing IncRNA NEAT1, Contributing to Tumorigenesis and Immune Evasion in Glioblastoma. Frontiers in Immunology, 2021, 12, 802795.	4.8	14
17	Vocal cord paralysis due to ectopic parathyroid adenoma and function recovery: a case report and review of the literature. Endocrine Journal, 2020, 67, 161-165.	1.6	1
18	Radiomics Analysis of Postoperative Epilepsy Seizures in Low-Grade Gliomas Using Preoperative MR Images. Frontiers in Oncology, 2020, 10, 1096.	2.8	11

#	Article	IF	CITATIONS
19	Targeting CLK3 inhibits the progression of cholangiocarcinoma by reprogramming nucleotide metabolism. Journal of Experimental Medicine, 2020, 217, .	8.5	42
20	PD-L1-Mediated Immunosuppression in Glioblastoma Is Associated With the Infiltration and M2-Polarization of Tumor-Associated Macrophages. Frontiers in Immunology, 2020, 11, 588552.	4.8	80
21	Intrapericardial parathyroid carcinoma: a case report. Endocrine, 2020, 69, 456-460.	2.3	7
22	<scp>UHMK</scp> 1 promotes gastric cancer progression through reprogramming nucleotide metabolism. EMBO Journal, 2020, 39, e102541.	7.8	32
23	Predicting the Type of Tumor-Related Epilepsy in Patients With Low-Grade Gliomas: A Radiomics Study. Frontiers in Oncology, 2020, 10, 235.	2.8	19
24	Radiomics Features Predict Telomerase Reverse Transcriptase Promoter Mutations in World Health Organization Grade II Gliomas via a Machine-Learning Approach. Frontiers in Oncology, 2020, 10, 606741.	2.8	13
25	Association of tumor growth rates with molecular biomarker status: a longitudinal study of high-grade glioma. Aging, 2020, 12, 7908-7926.	3.1	6
26	Crispr Library Screening: Genomeâ€Wide CRISPRâ€Cas9 Screening Identifies NFâ€Î°B/E2F6 Responsible for EGFRvIIIâ€Associated Temozolomide Resistance in Glioblastoma (Adv. Sci. 17/2019). Advanced Science, 2019, 6, 1970103.	11,2	0
27	Collateral Effects: The CRISPRâ€Cas13a Geneâ€Editing System Induces Collateral Cleavage of RNA in Glioma Cells (Adv. Sci. 20/2019). Advanced Science, 2019, 6, 1970124.	11.2	0
28	Radiogenomic analysis of vascular endothelial growth factor in patients with diffuse gliomas. Cancer Imaging, 2019, 19, 68.	2.8	20
29	Radiogenomic analysis of PTEN mutation in glioblastoma using preoperative multi-parametric magnetic resonance imaging. Neuroradiology, 2019, 61, 1229-1237.	2.2	21
30	Dualâ€Specificity Tyrosine Phosphorylation–Regulated Kinase 3 Loss Activates Purine Metabolism and Promotes Hepatocellular Carcinoma Progression. Hepatology, 2019, 70, 1785-1803.	7.3	28
31	Gene Expression Profiling Stratifies IDH-Wildtype Glioblastoma With Distinct Prognoses. Frontiers in Oncology, 2019, 9, 1433.	2.8	16
32	Amino acid metabolismâ€related gene expressionâ€based risk signature can better predict overall survival for glioma. Cancer Science, 2019, 110, 321-333.	3.9	39
33	ISG20 promotes local tumor immunity and contributes to poor survival in human glioma. Oncolmmunology, 2019, 8, e1534038.	4.6	39
34	IDH mutation-specific radiomic signature in lower-grade gliomas. Aging, 2019, 11, 673-696.	3.1	51
35	Single-cell RNA-seq reveals RAD51AP1 as a potent mediator of EGFRvIII in human glioblastomas. Aging, 2019, 11, 7707-7722.	3.1	13
36	Effects of an individualized nutrition intervention on the respiratory quotient of patients with liver failure. Asia Pacific Journal of Clinical Nutrition, 2019, 28, 428-434.	0.4	0

#	Article	IF	CITATIONS
37	The Differentially Expressed Genes of Human Sporadic Cerebral CavernousÂMalformations. World Neurosurgery, 2018, 113, e247-e270.	1.3	4
38	Genotype prediction of ATRX mutation in lower-grade gliomas using an MRI radiomics signature. European Radiology, 2018, 28, 2960-2968.	4.5	91
39	Molecular and clinical characterization of IDH associated immune signature in lower-grade gliomas. Oncolmmunology, 2018, 7, e1434466.	4.6	53
40	Molecular profiles for insular low-grade gliomas with putamen involvement. Journal of Neuro-Oncology, 2018, 138, 659-666.	2.9	7
41	Clinical characteristics associated with postoperative seizure control in adult low-grade gliomas: a systematic review and meta-analysis. Neuro-Oncology, 2018, 20, 324-331.	1.2	32
42	MRI features can predict EGFR expression in lower grade gliomas: A voxel-based radiomic analysis. European Radiology, 2018, 28, 356-362.	4.5	101
43	MRI features predict p53 status in lower-grade gliomas via a machine-learning approach. Neurolmage: Clinical, 2018, 17, 306-311.	2.7	85
44	Regional specificity of $1p/19q$ co-deletion combined with radiological features for predicting the survival outcomes of anaplastic oligodendroglial tumor patients. Journal of Neuro-Oncology, 2018, 136, 523-531.	2.9	7
45	Prognostic value of a microRNA signature as a novel biomarker in patients with lower-grade gliomas. Journal of Neuro-Oncology, 2018, 137, 127-137.	2.9	66
46	A comprehensive review of available omics data resources and molecular profiling for precision glioma studies (Review). Biomedical Reports, 2018, 10, 3-9.	2.0	7
47	ALDH1A3 induces mesenchymal differentiation and serves as a predictor for survival in glioblastoma. Cell Death and Disease, 2018, 9, 1190.	6. 3	42
48	A radiomic signature as a non-invasive predictor of progression-free survival in patients with lower-grade gliomas. Neurolmage: Clinical, 2018, 20, 1070-1077.	2.7	145
49	PRMT2 links histone H3R8 asymmetric dimethylation to oncogenic activation and tumorigenesis of glioblastoma. Nature Communications, 2018, 9, 4552.	12.8	72
50	Genetic and clinical characterization of B7â€H3 (CD276) expression and epigenetic regulation in diffuse brain glioma. Cancer Science, 2018, 109, 2697-2705.	3.9	73
51	MEGF10, a Glioma Survival-Associated Molecular Signature, Predicts IDH Mutation Status. Disease Markers, 2018, 2018, 1-8.	1.3	9
52	The role of PTRF/Cavin1 as a biomarker in both glioma and serum exosomes. Theranostics, 2018, 8, 1540-1557.	10.0	96
53	Radiomics analysis allows for precise prediction of epilepsy in patients with low-grade gliomas. NeuroImage: Clinical, 2018, 19, 271-278.	2.7	67
54	Molecular profiles of tumor contrast enhancement: A radiogenomic analysis in anaplastic gliomas. Cancer Medicine, 2018, 7, 4273-4283.	2.8	9

#	Article	IF	CITATIONS
55	Radiogenomics of lower-grade gliomas: a radiomic signature as a biological surrogate for survival prediction. Aging, 2018, 10, 2884-2899.	3.1	29
56	Treatment strategy and IDH status improve nomogram validity in newly diagnosed GBM patients. Neuro-Oncology, 2017, 19, 736-738.	1.2	20
57	miR-181d/MALT1 regulatory axis attenuates mesenchymal phenotype through NF-κB pathways in glioblastoma. Cancer Letters, 2017, 396, 1-9.	7.2	50
58	Anatomic Location of Tumor Predicts the Accuracy of Motor Function Localization in Diffuse Lower-Grade Gliomas Involving the Hand Knob Area. American Journal of Neuroradiology, 2017, 38, 1990-1997.	2.4	24
59	Radiomic features predict Ki-67 expression level and survival in lower grade gliomas. Journal of Neuro-Oncology, 2017, 135, 317-324.	2.9	48
60	Tumor Purity as an Underlying Key Factor in Glioma. Clinical Cancer Research, 2017, 23, 6279-6291.	7.0	372
61	Molecular and clinical characterization of TIM-3 in glioma through 1,024 samples. Oncolmmunology, 2017, 6, e1328339.	4.6	114
62	The Landscape of Viral Expression Reveals Clinically Relevant Viruses with Potential Capability of Promoting Malignancy in Lower-Grade Glioma. Clinical Cancer Research, 2017, 23, 2177-2185.	7.0	12
63	ADAM9 Expression Is Associate with Glioma Tumor Grade and Histological Type, and Acts as a Prognostic Factor in Lower-Grade Gliomas. International Journal of Molecular Sciences, 2016, 17, 1276.	4.1	27
64	FGFR3, as a receptor tyrosine kinase, is associated with differentiated biological functions and improved survival of glioma patients. Oncotarget, 2016, 7, 84587-84593.	1.8	10
65	Molecular and clinical characterization of PD-L1 expression at transcriptional level via 976 samples of brain glioma. Oncolmmunology, 2016, 5, e1196310.	4.6	176
66	The relation between angioarchitectural factors of developmental venous anomaly and concomitant sporadic cavernous malformation. BMC Neurology, 2016, 16, 183.	1.8	11
67	Brain regions associated with telomerase reverse transcriptase promoter mutations in primary glioblastomas. Journal of Neuro-Oncology, 2016, 128, 455-462.	2.9	9
68	Human leukocyte antigen-G overexpression predicts poor clinical outcomes in low-grade gliomas. Journal of Neuroimmunology, 2016, 294, 27-31.	2.3	11
69	CGCG clinical practice guidelines for the management of adult diffuse gliomas. Cancer Letters, 2016, 375, 263-273.	7.2	448
70	Putamen involvement and survival outcomes in patients with insular low-grade gliomas. Journal of Neurosurgery, 2016, 126, 1788-1794.	1.6	22
71	Effect of transcutaneous acupoint electrical stimulation on propofol sedation: an electroencephalogram analysis of patients undergoing pituitary adenomas resection. BMC Complementary and Alternative Medicine, 2016, 16, 33.	3.7	12
72	Intraoperative and Postoperative Anaesthetic and Analgesic Effect of Multipoint Transcutaneous Electrical Acupuncture Stimulation Combined with Sufentanil Anaesthesia in Patients Undergoing Supratentorial Craniotomy. Acupuncture in Medicine, 2015, 33, 270-276.	1.0	43